← Back to Search

Chemotherapy

Ultrasound for Detecting Chemotherapy-Induced Peripheral Neuropathy

N/A
Recruiting
Led By Roy Strowd, MD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Gastrointestinal cancer
Colorectal cancer (any stage)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 30 days
Awards & highlights

Study Summary

This trial looks at using ultrasound to detect neuropathy in gastrointestinal cancer patients caused by the chemotherapy drug oxaliplatin.

Who is the study for?
This trial is for patients with any stage of gastrointestinal or colorectal cancer who are currently or have previously been treated with oxaliplatin-based chemotherapy and now show signs of peripheral neuropathy. Participants must be able to understand and sign a consent form.Check my eligibility
What is being tested?
The study is testing the effectiveness of ultrasound in detecting neuropathy caused by oxaliplatin in gastrointestinal cancer patients. It involves nerve exams, skin biopsies, nerve conduction studies, blood draws, and questionnaires about chemotherapy-induced peripheral neuropathy.See study design
What are the potential side effects?
Potential side effects may include discomfort from the ultrasound procedure on nerves, minor pain or bruising from skin biopsies and blood draws, as well as possible emotional distress from discussing symptoms.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have cancer in my digestive system.
Select...
I have been diagnosed with colorectal cancer.
Select...
I am currently or have previously been treated with oxaliplatin-based chemotherapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Tibial Nerve Cross-Sectional Area Comparison
Secondary outcome measures
Amplitude of Nerve Response of Sural Nerve
Amplitude of Nerve Response of Tibial Nerve
Conduction Velocity of Nerve Response of Sural Nerve
+6 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: UltrasoundExperimental Treatment6 Interventions
Undergo peripheral nerve ultrasound
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Skin Biopsy
2015
Completed Phase 4
~680
Nerve Conduction Study
2009
N/A
~170

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,241 Previous Clinical Trials
1,004,217 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,660 Previous Clinical Trials
40,924,501 Total Patients Enrolled
Roy Strowd, MDPrincipal InvestigatorWake Forest University Health Sciences
6 Previous Clinical Trials
114 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy
2019. "Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03958747.
All > Colorectal Cancer Raleigh > Peripheral Neuropathy
~0 spots leftby Jun 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top